| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.62M | 7.62M | 7.23M | 4.98M | 4.43M | 735.44K |
| Gross Profit | 1.50M | 1.50M | 6.74M | -2.44M | 4.14M | -2.03M |
| EBITDA | 275.62K | 275.62K | -826.62K | -2.65M | -5.90M | -5.06M |
| Net Income | -72.20K | -72.20K | -2.67M | -4.33M | -5.25M | -5.23M |
Balance Sheet | ||||||
| Total Assets | 5.94M | 5.94M | 6.82M | 7.57M | 8.02M | 12.23M |
| Cash, Cash Equivalents and Short-Term Investments | 1.05M | 1.05M | 1.25M | 1.85M | 4.50M | 8.90M |
| Total Debt | 2.37M | 2.37M | 192.98K | 961.96K | 0.00 | 75.28K |
| Total Liabilities | 4.42M | 4.42M | 3.30M | 4.02M | 1.72M | 2.61M |
| Stockholders Equity | 1.52M | 1.52M | 1.97M | 2.14M | 6.30M | 9.61M |
Cash Flow | ||||||
| Free Cash Flow | -804.93K | -804.93K | -2.59M | -3.42M | -4.54M | -1.52M |
| Operating Cash Flow | -732.06K | -732.06K | -1.30M | -2.53M | -4.52M | -1.50M |
| Investing Cash Flow | 119.16K | 119.16K | -570.80K | -799.63K | -256.83K | -23.21K |
| Financing Cash Flow | 370.14K | 400.96K | 1.27M | 687.55K | 8.81M | 1.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$63.69M | -7.09 | -8647.54% | ― | 25.98% | 22.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | ― | ― | 3.02% | ― | 5.42% | 97.46% | |
41 Neutral | AU$6.16M | -7.05 | ― | ― | -9.90% | 34.07% | |
40 Underperform | AU$16.45M | -0.24 | -240.60% | ― | -48.41% | -7200.00% | |
40 Underperform | AU$84.39M | -11.89 | ― | ― | ― | ― | |
34 Underperform | AU$10.99M | -3.75 | ― | ― | 241.34% | 44.19% |
Careteq Ltd. has released its 2025 Corporate Governance Statement, detailing its adherence to the ASX Corporate Governance Principles and Recommendations. The company emphasizes its commitment to maintaining shareholder value, ethical conduct, and compliance with legal standards. The statement outlines the roles and responsibilities of the board and management, the company’s diversity policy, and the processes for evaluating the performance of the board and senior executives. This governance framework aims to strengthen Careteq’s operational integrity and stakeholder trust.
Careteq Limited has reported a significant turnaround in its financial performance for FY25, achieving a group EBITDA profit from continuing operations of $0.3 million, compared to a loss in the previous year. This improvement is attributed to strategic decisions, including divesting the loss-making Sofihub business and acquiring the remaining stake in the profitable Embedded Health Solutions (EHS) unit. The company expects continued revenue growth and positive EBITDA in FY26, driven by synergies from integrating its platforms and partnerships with national GP networks.
Careteq Limited reported a significant reduction in its loss for the year ended June 30, 2025, with a 97.3% decrease to $72,204 compared to the previous year. Despite a 7.1% decline in revenues, the company’s financial performance improved, reflecting effective cost management and strategic consolidation efforts, including the acquisition of Embedded Health Solutions Pty Ltd.